For the second quarter of 2009, the company has reported total revenue of $628.67 million, compared to $571.5 million for the corresponding period of 2008.

Celegne has reported a net income of $305.72 million, or $0.65 per share, for the first half of 2009, compared to a net loss of 1.52 billion, or $3.56 per share, for the first half of 2008. The company has reported total revenue of $1.23 billion for the first half of 2009, compared to $1.03 billion for the same period of 2008.

Sol Barer, chairman and CEO of Celgene, said: "The second quarter was one of exceptional results across many functions, including significant progress on the commercial, clinical, and financial fronts. We continue to launch our best-in-class therapies across the globe and now have sales and operations in more than 70 countries.

"We are pleased with the continued market share and durations gains achieved by Revlimid during the quarter, progress that is particularly encouraging given the challenging economic environment. Finally, we are looking forward to reporting data from multiple key clinical trials throughout the remainder of 2009 as we advance our deep and diverse clinical pipeline."

A service of YellowBrix, Inc.